Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) has joined a Canadian oncology research consortium as a co-applicant in a competitive Terry Fox Research Institute grant to support the development of Onco-Innovations’ SynoGraph(TM) artificial intelligence platform. The collaboration aims to investigate whether causal AI, combined with preclinical research and real-world clinical, genomic, and imaging data, can enhance predictions of how investigational therapies may perform in human trials.
Under the project, Redwood AI will contribute proprietary data integration, feature engineering, and physicochemical modelling methods. The company will work alongside Onco-Innovations and academic research partners that will supply clinical and genomic datasets. This partnership expands Redwood AI’s applications in life sciences and highlights the potential of combining AI with chemical modelling to support drug development.
The initiative matters because it could accelerate the development of new therapies by improving the accuracy of early-stage predictions, potentially reducing the time and cost associated with bringing drugs to market. By integrating causal AI with diverse data sources, the consortium hopes to create a more robust framework for evaluating investigational therapies before they enter human trials.
Redwood AI is a technology company developing advanced artificial intelligence and cybersecurity solutions for defense, public safety, and life sciences. Its technology is designed to help organizations prepare for quantum-enabled cybersecurity threats while enabling faster, more efficient development of new therapies and chemistry-driven applications. For more information about Redwood AI, visit Redwood AI Corp.. The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF.
The announcement was disseminated through AINewsWire, a specialized communications platform focused on advancements in artificial intelligence. AINewsWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For full terms of use and disclaimers applicable to all content provided by AINW, see https://www.AINewsWire.com/Disclaimer. To view the full article, visit https://ibn.fm/aMe02.
